US Stock MarketDetailed Quotes

RNAZ Transcode Therapeutics

Watchlist

0.507
-0.008-1.59%

Close Nov 5 16:00 ET

0.510
+0.003+0.53%

Pre 08:17 ET

8.75MMarket Cap-205P/E (TTM)

Transcode Therapeutics Stock Forum

Trytosaveabit

Oct 23 06:01

News

$Transcode Therapeutics (RNAZ.US)$ Reuters· just
Transcode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 Ttx-Mc138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data

Daily Investors

Oct 22 05:08

SNAP, GNPZ,RNAZ,BNAT

Four companies today that have the potential to explode. GNPX,The first has already exploded, and has warnings from several analysts that it's going to keep going. Next you have SNAP. They have their earnings Today. Named on Zacks as a potential win, and with a History to Blow up. Worth the shot. Next these two companies are the new maxn and muln. They are BNAT && RNAZ. Both Green after a major mountain of interest collapsed, just to tise back up today 🤫

Teddy123

Oct 10 23:44

TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology

$Transcode Therapeutics (RNAZ.US)$
BOSTON, Oct. 10, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has dosed all patients in the first cohort of its Phase 1a dose-escalation clinical trial. The therapeutic candidate being e...

Jaguar8

Oct 10 06:13

NEWS

$Transcode Therapeutics (RNAZ.US)$
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
TransCode Therapeutics (NASDAQ: RNAZ) has completed initial dosing of the first cohort in its Phase 1a dose-escalation clinical trial for TTX-MC138, an antisense oligonucleotide designed to inhibit microRNA-10b, a driver of metastasis in multiple cancers. Key points:
All patients in the cohort received their first dose an...